LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus

Starting soon · Phase 2

Conditions studied: Left Ventricular Thrombus

In brief

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are: * To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement. * To identify the optimal length of anticoagulation in the treatment of LV Thrombus After randomisation participants will: * Continue their prescribed oral anticoagulant for the remainder of the trial * Discontinue their prescribed oral anticoagulant for the remainder of the trial

Key facts

Study ID

NCT07246005

Run by

Queen Mary University of London

People needed

120

Starts

2026-12-01

Expected to finish

2027-12-01

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of LV thrombus less than 12 months ago
• On Apixaban at the time of randomisation
• Completed at least 3 months of anticoagulation treatment for LV thrombus
• Persistent laminar/ mural thrombus or persistent LV dysfunction

You may not qualify if…

• Any clinical condition requiring long term anticoagulation treatment as per investigator's judgement.
• SSE since LV thrombus diagnosis
• Contraindication to continuing anticoagulation therapy
• Non-ischaemic Cardiomyopathy
• Age less than 18 years
• Unable to consent

Where it is running

• St Bartholomews Hospital — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.